Components of an integrated microfluidic device for continuous glucose monitoring with responsive insulin delivery.

Diabetes Technol Ther

Department of Bioengineering, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.

Published: June 2005

Miniaturized medical diagnostic and treatment devices are currently being developed. Microneedles and miniaturized microdialysis systems are particularly well suited to impact diabetes treatment for continuous glucose monitoring and feedback-controlled insulin delivery. Microneedles are an attractive advanced drug delivery system used to mechanically penetrate the skin and inject insulin intradermally where it is rapidly absorbed by the capillary bed into the bloodstream. The real advantage of microneedle-enhanced drug delivery lies in the fact that drug is actively injected into a patient so the dosage may be varied with time to allow complex drug delivery profiles. The delivery is independent of the drug composition and merely relies on the subsequent drug absorption into the bloodstream. A miniaturized microdialysis probe for continuous glucose sensing has also been designed. Microdialysis is based upon controlling the mass transfer rate of glucose diffusing across a semipermeable membrane into a dialysis fluid while excluding larger molecules such as proteins. Polymer microdialysis membranes are integrated with microfluidic systems. Because of the high surface area to fluid volume ratio of miniaturized fluid channels, faster recovery of glucose to increase glucose sensing frequency is expected. This work highlights recent advances made in the design and fabrication of microneedles to make them more biocompatible and more fracture resistant in order to effectively enter the biomedical market. In addition, the design of a miniaturized microdialysis system for increased glucose sampling frequency is presented. The sensing and infusion technologies may be combined into a miniaturized "artificial pancreas" for minimally invasive feedback-controlled insulin delivery.

Download full-text PDF

Source
http://dx.doi.org/10.1089/dia.2005.7.536DOI Listing

Publication Analysis

Top Keywords

continuous glucose
12
insulin delivery
12
miniaturized microdialysis
12
drug delivery
12
integrated microfluidic
8
glucose monitoring
8
feedback-controlled insulin
8
glucose sensing
8
glucose
7
delivery
7

Similar Publications

Coccidioidomycosis is an endemic fungal infection caused by the soil-dwelling Coccidioides immitis/posadasii. One prior study showed that persons with diabetes mellitus (DM) with elevated glucose at the time of coccidioidomycosis had poorer coccidioidal outcomes compared to persons without DM. The purpose of this study was to assess the association between hemoglobin A1C (A1C) and outcomes among persons with coccidioidomycosis and co-existing DM.

View Article and Find Full Text PDF

With the rise in fast-food culture and the continued high numbers of tobacco-related deaths, there has been a great deal of interest in understanding the relationship between high-fat diet (HFD) and nicotine use behaviors. Using adult mice and a patch-clamp electrophysiology assay, we investigated the influence of HFD on the excitability of ventral tegmental area (VTA) dopamine neurons and pyramidal neurons in the medial prefrontal cortex (mPFC) given their role in modulating the reinforcing effects of nicotine and natural rewards. We then examined whether HFD-induced changes in peripheral markers were associated with nicotine use behaviors.

View Article and Find Full Text PDF

This study evaluated a next-generation automated insulin delivery (AID) algorithm for Omnipod in type 1 and type 2 diabetes across multiple phases: 14-day run-in with usual therapy, 48-h AID use in a hotel setting (type 1 only), and up to 6 weeks of outpatient AID use. Participants did, or did not, deliver manual boluses at alternating periods. Twelve adults with type 1 diabetes completed the hotel phase; 9 of those 12 plus 8 adults with type 2 diabetes completed the subsequent outpatient phase.

View Article and Find Full Text PDF

The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes.

View Article and Find Full Text PDF

Impact of time in tight range on all-cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study.

Diabetes Obes Metab

January 2025

Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai, China.

Aims: Currently, there is a lack of evidence regarding time in tight range (TITR) and long-term adverse outcomes. We aimed to investigate the association between TITR and the risk of all-cause and cardiovascular mortality among patients with type 2 diabetes.

Materials And Methods: A total of 6061 patients with type 2 diabetes were prospectively recruited in a single centre.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!